<DOC>
	<DOCNO>NCT00154219</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability , safety investigational drug , lumiracoxib compare celecoxib placebo subject hip osteoarthritis . Both lumiracoxib celecoxib belong class drug ( COX-2 selective nonsteroidal anti-inflammatory drug [ NSAIDs ] ) .</brief_summary>
	<brief_title>Efficacy Safety Study Lumiracoxib Patients With Primary Hip Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Diagnosis primary hip osteoarthritis Qualifying pain intensity hip joint Requiring NSAID therapy Rheumatoid arthritis inflammatory joint disease Disease disorder may interfere pain assessment hip Open knee/hip surgery within last year Past history heart attack , stroke angina ( chest pain ) Liver disorder History severe adverse reaction kind lumiracoxib celecoxib treatment Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis , Hip , Lumiracoxib , Efficacy , Safety</keyword>
</DOC>